After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring

Novo Nordisk's recent licensing deal, worth over $1 billion, has sent the stock of a Swedish company skyrocketing, following a disappointing capital-markets day that left investors uncertain about the company's future direction. This strategic move highlights Novo's commitment to expanding its portfolio and could signal a turnaround in investor confidence. The deal's substantial value underscores the potential for significant growth and innovation in the pharmaceutical sector, providing a much-needed boost after a period of market uncertainty.